Cargando…

Carvedilol Ameliorates Intrahepatic Angiogenesis, Sinusoidal Remodeling and Portal Pressure in Cirrhotic Rats

BACKGROUND: Carvedilol is the first-line drug for the primary prophylaxis of variceal bleeding due to portal hypertension (PHT) in liver cirrhosis. This study aimed to investigate the effects of carvedilol on intrahepatic angiogenesis and sinusoidal remodeling in cirrhotic rats and explore the under...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ling, Liping, Li, Guangqi, Meng, Dongxiao, Wang, Sining, Zhang, Chunqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2018
Materias:	Animal Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253986/ https://www.ncbi.nlm.nih.gov/pubmed/30448852 http://dx.doi.org/10.12659/MSM.913118

Ejemplares similares

Carvedilol—NSBB of Choice in All Cirrhotics? Short Title: Carvedilol for Portal Hypertension
por: Tandon, Puneeta, et al.
Publicado: (2015)

Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis
por: Ling, Liping, et al.
Publicado: (2019)

Celecoxib Ameliorates Portal Hypertension of the Cirrhotic Rats through the Dual Inhibitory Effects on the Intrahepatic Fibrosis and Angiogenesis
por: Gao, Jin-Hang, et al.
Publicado: (2013)

Lowering hepatic venous pressure agent carvedilol versus variceal banding ligation for clinical outcomes of cirrhotic portal hypertension
por: Wei, Zhen-gang, et al.
Publicado: (2018)

Diagnostic challenges in non-cirrhotic portal hypertension - porto sinusoidal vascular disease
por: Nicoară-Farcău, Oana, et al.
Publicado: (2020)

Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats
por: Gao, Jin-Hang, et al.
Publicado: (2016)

Correction: Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats
por: Gao, Jin-Hang, et al.
Publicado: (2022)

Carvedilol in the Treatment of Portal Hypertension
por: Al-Ghamdi, Hamdan
Publicado: (2011)

Portal vein thrombosis leading to pre-sinusoidal non-cirrhotic portal hypertension resulting in decreased synthetic function of the liver
por: Kline, Kevin, et al.
Publicado: (2019)

Idiopathic Non-Cirrhotic Portal Hypertension and Porto-Sinusoidal Vascular Disease: Review of Current Data
por: Kmeid, Michel, et al.
Publicado: (2021)

Carvedilol attenuates carbon tetrachloride-induced liver fibrosis and hepatic sinusoidal capillarization in mice
por: Wu, Ying, et al.
Publicado: (2019)

Transjugular intrahepatic portosystemic shunt with radioactive seed strand for main portal vein tumor thrombosis with cirrhotic portal hypertension
por: Yan, Xuan-Hui, et al.
Publicado: (2022)

Carvedilol Inhibits Angiotensin II-Induced Proliferation and Contraction in Hepatic Stellate Cells through the RhoA/Rho-Kinase Pathway
por: Wu, Ying, et al.
Publicado: (2019)

Portal Fibrotic Cord is Associated with Transjugular Intrahepatic Portosystemic Shunt Failure and Death in Cirrhotic Patients
por: Yang, Yunshu, et al.
Publicado: (2023)

Agreement between Wedged Hepatic Venous Pressure and Portal Pressure in Hepatic Sinusoidal Obstruction Syndrome
por: Cheng, Yang, et al.
Publicado: (2022)

Cirrhotic Endothelial Progenitor Cells Enhance Liver Angiogenesis and Fibrosis and Aggravate Portal Hypertension in Bile Duct-Ligated Cirrhotic Rats
por: Tripathi, Dinesh Mani, et al.
Publicado: (2020)

Fuzhenghuayu Decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis
por: Liu, Hong-liang, et al.
Publicado: (2019)

Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis
por: Li, Tong, et al.
Publicado: (2016)

Systematic review and meta-analysis of trans-jugular intrahepatic portosystemic shunt for cirrhotic patients with portal vein thrombosis
por: Zhang, Jian-Bin, et al.
Publicado: (2021)

Glycyrrhizin Attenuates Portal Hypertension and Collateral Shunting via Inhibition of Extrahepatic Angiogenesis in Cirrhotic Rats
por: Pun, Chon Kit, et al.
Publicado: (2021)

Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial
por: Qi, Xingshun, et al.
Publicado: (2013)

Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats
por: Gunarathne, Lakmie S., et al.
Publicado: (2019)

Qishen Yiqi Dropping Pills Ameliorates Doxorubicin-Induced Cardiotoxicity in Mice via Enhancement of Cardiac Angiogenesis
por: Wang, Lijiang, et al.
Publicado: (2019)

Increased sinusoidal pressure impairs liver endothelial mechanosensing, uncovering novel biomarkers of portal hypertension
por: Ortega-Ribera, Martí, et al.
Publicado: (2023)

Presumptive non‐cirrhotic bleeding esophageal varices in a dog
por: Myers, Marc, et al.
Publicado: (2018)

The effect of carvedilol and propranolol on portal hypertension in patients with cirrhosis: a meta-analysis
por: Chen, Sheng, et al.
Publicado: (2015)

CARVEDILOL AS PRIMARY PROPHYLAXIS FOR GASTRIC VARICEAL BLEEDING IN PORTAL HYPERTENSION MODEL IN RATS
por: BERTOLDI, Andressa de Souza, et al.
Publicado: (2020)

Carvedilol Ameliorates Experimental Atherosclerosis by Regulating Cholesterol Efflux and Exosome Functions
por: Chen, Sy-Jou, et al.
Publicado: (2019)

Effects of Baicalin on Blood Pressure and Left Ventricular Remodeling in Rats with Renovascular Hypertension
por: Dai, Hualei, et al.
Publicado: (2017)

The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
por: Schwabl, Philipp, et al.
Publicado: (2018)

Wall shear stress in portal vein of cirrhotic patients with portal hypertension
por: Wei, Wei, et al.
Publicado: (2017)

The Efficacy of Carvedilol in Comparison to Propranolol in Reducing the Hepatic Venous Pressure Gradient and Decreasing the Risk of Variceal Bleeding in Adult Cirrhotic Patients: A Systematic Review
por: Dardari, Lana, et al.
Publicado: (2023)

Effect of endotoxemia on hepatic portal and sinusoidal blood flow in rats
por: Secchi, A, et al.
Publicado: (1999)

Enantioselective Resolution of (R,S)-Carvedilol to (S)-(−)-Carvedilol by Biocatalysts
por: Ettireddy, Swetha, et al.
Publicado: (2017)

Management of Portal Vein Thrombosis in Cirrhotic Patients
por: Amitrano, Lucio, et al.
Publicado: (2009)

Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension
por: Biecker, Erwin
Publicado: (2013)

Causes and Management of Non-cirrhotic Portal Hypertension
por: Gioia, Stefania, et al.
Publicado: (2020)

Hypoxia-Inducible Factor 1 alpha (HIF-1α)/Vascular Endothelial Growth Factor (VEGF) Pathway Participates in Angiogenesis of Myocardial Infarction in Muscone-Treated Mice: Preliminary Study
por: Du, Yingqiang, et al.
Publicado: (2018)

Immune Regulation of Intrahepatic Regulatory T Cells in Fibrotic Livers of Mice
por: Zhang, Xiaohui, et al.
Publicado: (2017)

Carvedilol Ameliorates Early Diabetic Nephropathy in Streptozotocin-Induced Diabetic Rats
por: Morsy, Mohamed A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b7llb8os3egnk2mb0ihrn9it8h